U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414940) titled 'ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium' on Aug. 22, 2024.
Brief Summary: Advanced metastatic castration-resistant prostate cancer is a medical condition for which additional effective and tolerable treatments are urgently needed in order to improve patient outcomes and quality of life.
The goal of this clinical trial is to learn more about Actinium (225Ac) radiohybrid prostate-specific membrane antigen-10.1 (rhPSMA-10.1) injection in men with prostate cancer that has spread and progressed after previous treatments, particularly after Lutetium-PSMA.
Actinium (225Ac) rhPSMA-10.1 is an injectable radioactive me...